share_log
Benzinga ·  May 9 07:39
Larimar Therapeutics' Cash, Cash Equivalents, And Marketable Securities Of $239M As Of March 31, 2024, Extends Projected Cash Runway Into 2026
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment